

Product News

Bensal HP

Valeant Dermatology introduces Bensal HP ointment in a 30-g tube. Bensal HP is a topical salicylic acid treatment for inflammation and irritation associated with many common forms of dermatitis, including certain eczematoid conditions. These conditions include complications associated with pyodermas. Bensal HP reduces methicillin-resistant *Staphylococcus aureus* protected by biofilms in wounds using porcine models and stimulates reepithelialization of second-degree burns. It should be applied twice daily for best results. For more information, visit www.bensalhprx.com.

Cloderm Cream

Promius Pharma, LLC, introduces an authorized generic (AG) form of Cloderm Cream (clocortolone pivalate 0.1%), which will provide patients and physicians with the same clinical benefits of the Cloderm Cream brand with the potential to increase access to this treatment. The AG formulation contains the same trio of occlusive, humectant, and emollient ingredients as Cloderm Cream. Both are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. The AG formulation will be available in the same sizes as the branded cream: 45- and 90-g tubes and a 75-g pump. Eligible patients can use an updated \$0 copay savings program coupon for either the AG or branded versions of clocortolone pivalate cream 0.1%.

Effaclar Dermatological Acne System

La Roche-Posay Laboratoire Dermatologique introduces the Effaclar Dermatological Acne System for over-the-counter treatment of acne. The Effaclar Dermatological Acne System (available in April 2014) is designed to reduce acne and improve the skin's condition within 3 days with little to no drying or irritation. It also provides continuous treatment of blemishes and comedones. The system consists of the new Effaclar Medicated Gel Cleanser, the new Effaclar Clarifying Solution, and Effaclar Duo. Salicylic acid and lipohydroxy acid in the cleanser target excessive oil. The solution is formulated with glycolic acid and salicylic acid to target clogged pores. Effaclar Duo contains micronized benzoyl peroxide to treat acne. For more information, visit www.laroche-posay.us.

Glytone by Ducray

Pierre Fabre Dermo-Cosmétique USA introduces Glytone by Ducray with 2 ranges of hair care solutions for hair loss and scaly scalp. The Glytone by Ducray hair loss range is formulated to target the

factors that influence healthy hair growth with formulas for both occasional and chronic hair thinning/loss. Products include Anaphase Cream Shampoo for both occasional and chronic hair loss to help nourish and strengthen weak thinning hair and prepare the scalp for hair-loss treatments; Neopeptide Hair Lotion Spray for chronic hair loss to encourage healthy hair growth; Anastim Hair Lotion Concentrate for occasional hair loss to stimulate the scalp and optimize the delivery of nutrients essential for strength, body, shine, and volume to the hair bulb; and Anacaps Dietary Supplement for both occasional and chronic hair loss to help strengthen hair and encourage healthy growth.

The Glytone by Ducray scaly scalp range targets mild to severe scaly scalp conditions, helping to calm irritation and itching as well as improve the appearance of the scalp. Products include Elution Shampoo for a fragile scalp to soothe and protect; Kertyol PSO Shampoo for a scaly irritated scalp to soothe redness; and Kelual DS Shampoo for a severe scaly scalp to calm and soothe severe squamous conditions. For more information, visit www.glytone-usa.com.

Luzu

Valeant Pharmaceuticals International, Inc, announces that the new drug application for Luzu (luliconazole cream 1%) has been approved by the US Food and Drug Administration. Luzu is indicated for the topical treatment of interdigital tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm) caused by the organisms *Trichophyton rubrum* and *Epidermophyton floccosum* in patients 18 years and older. Luzu is a 1-week, once-daily therapy for tinea cruris and tinea corporis, which is a welcomed alternative to options that require longer treatment. Interdigital tinea pedis is approved as a 2-week, once-daily treatment. Approval in the United States follows 3 positive pivotal studies in 679 participants. In the 2 pivotal studies in tinea pedis with a treatment duration of 2 weeks, complete clearance (no clinical involvement and no evidence of fungus) 4 weeks posttreatment was achieved in 26% of participants in study 1 and 14% of participants in study 2. For the pivotal study in tinea cruris, complete clearance was assessed 3 weeks post-treatment. Complete clearance was achieved after 1 week of treatment in 21% of participants. For more information, visit www.valeant.com.

If you would like your product included in Product News, please e-mail a press release to the Editorial Office at cutis@frontlinemedcom.com.